NCT06033950View on ClinicalTrials.gov

A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists

PHASE3RecruitingINTERVENTIONAL
Enrollment

2,600

Participants

Timeline

Start Date

August 20, 2024

Primary Completion Date

March 31, 2028

Study Completion Date

April 30, 2028

Conditions
Heart Failure
Interventions
DRUG

Finerenone

Oral finerenone.

DRUG

Placebo

Matching oral placebo.

Trial Locations (8)

36532

RECRUITING

FIN-10004 Fairhope, AL Investigational Site, Fairhope

64111

RECRUITING

FIN-10002 Kansas City, MO Investigational Site, Kansas City

78705

RECRUITING

FIN-10015 Austin, TX Investigational Site, Austin

92243

RECRUITING

FIN-10075 San Diego, CA Investigational Site, San Diego

12916542

RECRUITING

FIN-21004 Braganca Paulista, Investigational Site, Bragança Paulista

74453-200

RECRUITING

FIN-21003 Goiania, Goias Investigational Site, Goiânia

05652-900

RECRUITING

FIN-21049 Sao Paulo, Investigational Site, Sao Paulp

V3V OC6

RECRUITING

FIN-11012 Surrey, BC Investigational Site, Surrey

All Listed Sponsors
collaborator

St. Luke's Hospital, Kansas City, Missouri

OTHER

collaborator

Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma

INDUSTRY

lead

Colorado Prevention Center

OTHER